Oncology Spotlight

Interviews with those who are working on the war against cancer. Brought to you by the ONCOassist team.

Oncology Spotlight is a health podcast hosted by Unknown Host, with 35 episodes on record and a Required Pod Score of 80.

Unknown Host hosts Oncology Spotlight, a health show with 35 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  Oncology Spotlight

  Oncology News: Trastuzumab deruxtecan EU Approval, Sevabertinib & Major Phase III Cancer Data

  Sep 17, 20262 min

  Latest Oncology News Four developments across breast cancer, lung cancer, multiple myeloma and prostate cancer. In this episode of Oncology Updates from ONCOassist , Dr. Stephanie Haddad reviews: HER2+ metastatic breast cancer: The European Commission has approved Enhertu (Trastuzumab deruxtecan) plus Pertuzumab as first-line treatment for adults with unresectable or metastatic HER2-positive breast cancer. In Phase III DESTINY-Breast09, the combination reduced the risk of disease progression or death by 44% versus THP, with median PFS of 40.7 vs 26.9 months. Relapsed/refractory multiple myeloma: Phase III CERVINO topline results showed an ORR of 74.0% with investigational Etentamig versus 45.7% with standard available therapies, alongside a 60% reduction in the risk of progression or death. Prostate cancer: The randomized STAMINA trial evaluated a 12-month supervised programme combining exercise, dietary advice and behavioural support for men receiving androgen deprivation therapy. Dr. Haddad reviews its reported effects on prostate cancer-specific quality of life, fatigue and overall cancer-related quality of life. HER2-mutated NSCLC: The FDA granted accelerated approval to Sevabertinib for adults with locally advanced or metastatic non-squamous NSCLC harbouring HER2/ERBB2 activating mutations, based on response rate and duration-of-response data from SOHO-01. Reference Links: https://www.astrazeneca.com/media-centre/press-releases/2026/enhertu-approved-in-eu-for-1l-her2-positive-mbc.html https://news.abbvie.com/2026-09-03-AbbVie-Announces-Positive-Topline-Results-from-the-Phase-3-CERVINO-Trial-Showing-Etentamig-Significantly-Improved-Response-Rate-and-Progression-Free-Survival-in-Patients-with-Relapsed-Refractory-Multiple-Myeloma https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00304-9/fulltext https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sevabertinib-locally-advanced-or-metastatic-non-squamous-non-small Oncology at your fingertips. Access the ONCOassist app: iOS, Android & Webapp: https://campaign.oncoassist.com/social-y

  ListenShow Notes
• 

  Oncology Spotlight

  Oncology News: mRNA Cancer Vaccine Milestone & New Pancreatic Cancer Approval

  Sep 4, 20263 min

  Latest Oncology News From a landmark mRNA-based individualized neoantigen therapy result in melanoma to an important advance in metastatic pancreatic cancer, this edition brings several major developments across oncology. Dr. Stephanie Haddad , Hematology/Oncology Fellow and Academic Chief Fellow at UT Health San Antonio/Mays Cancer Center, breaks down four updates oncology professionals should know. The FDA approved Daraxonrasib , a RAS inhibitor, for metastatic pancreatic adenocarcinoma following at least one prior systemic therapy or for patients not eligible for multi-agent chemotherapy. In RASolute 302 : Median OS: 13.2 vs 6.7 months Median PFS: 7.2 vs 3.6 months Response rate: 30% vs 11% OS hazard ratio: 0.40 The European Commission approved Sacituzumab Govitecan + Pembrolizumab for first-line PD-L1-positive metastatic triple-negative breast cancer with CPS ≥10 . Together with its recent monotherapy approval for patients who are not candidates for immunotherapy, Sacituzumab govitecan-based options now extend across PD-L1 status in first-line metastatic TNBC. In ASCENT-04 , the combination reduced the risk of progression or death by 35% . The Phase III INTerpath-001 trial of Intismeran autogene + Pembrolizumab met its primary endpoint of recurrence-free survival and key secondary endpoint of distant metastasis-free survival in completely resected Stage IIB–IV melanoma. The study represents the first Phase III readout for an individualized neoantigen therapy or mRNA cancer therapy and the first to outperform Pembrolizumab alone in the adjuvant setting. Detailed results are expected at an upcoming congress, while overall survival remains immature. New quality-of-life and safety data from the Phase III ALINA trial build on the previously reported disease-free survival benefit with adjuvant Alectinib in resected ALK-positive NSCLC. Treatment discontinuation was lower with Alectinib than chemotherapy ( 5% vs 13% ), while quality of life improved early and was maintained for more than two years. Reference Links: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daraxonrasib-metastatic-pancreatic-adenocarcinoma https://www.gilead.com/news/news-details/2026/european-commission-expands-role-of-gileads-trodelvy-in-first-line-metastatic-triple-negative-breast-cancer-across-pd-l1-status https://www.merck.com/news/merck-and-moderna-announce-phase-3-interpath-001-trial-of-intismeran-autogene-plus-keytruda-met-endpoints-of-recurrence-free-survival-rfs-and-distant-metastasis-free-survival-dmfs-in-patient/ https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00283-4/fulltext --------------------------------------------------- Oncology at your fingertips. Access the ONCOassist app: iOS, Android & Webapp: https://campaign.oncoassist.com/social-y Daraxonrasib in metastatic pancreatic cancer️ Sacituzumab Govitecan + Pembrolizumab in TNBC Landmark Phase III mRNA melanoma result ALINA: Alectinib in ALK+ NSCLC

  ListenShow Notes
• 

  Oncology Spotlight

  Expert Insights: ASCO GU 2026 - Key Takeaways from Studies with Dr. Yüksel Ürün

  Mar 5, 202616 minS0

  <p>👉 Visit https://oncoassist.com/ to streamline patient care with cutting-edge tools, treatment protocols, and calculators! </p><p>🔬In this episode of Oncology Spotlight - Expert Insights, Dr Yüksel Ürün, medical oncologist at Ankara University, reviews key studies presented at the ASCO Genitourinary Cancers Symposium, 2026.</p><p>The discussion focuses on clinically relevant trial results across bladder cancer, kidney cancer, and metastatic prostate cancer, highlighting data that may influence treatment decisions in daily oncology practice.</p><p>Key Studies Discussed:• KEYNOTE-B15 trial – Enfortumab vedotin + pembrolizumab in muscle-invasive bladder cancer- https://www.asco.org/abstracts-presentations/256834</p><p> • LITESPARK-011 – Belzutifan + lenvatinib after I...

  ListenShow Notes
• 

  Oncology Spotlight

  Oncology Spotlight: Access, Equity & AI in Cancer Care with Dr. Shaqil Kassam

  Feb 17, 202627 minS0

  <p>👉 Visit https://oncoassist.com/ to streamline patient care with cutting-edge tools, treatment protocols, and calculators! </p><p>🔬In this episode of Oncology Spotlight, Dr. Shaqil Kassam shares a powerful perspective from the front lines of community oncology in Canada.</p><p>From drug access delays in publicly funded systems to the real-world challenges of administering bispecific therapies outside academic centers, this conversation dives into the complexity of modern oncology.</p><p>We also explore:</p><p>Community vs academic oncology – what truly differs?</p><p>The global equity gap in cancer care</p><p>How AI is already transforming clinic wo...

  ListenShow Notes
• 

  Oncology Spotlight

  Oncology Spotlight: Access, Equity & AI in Cancer Care - Dr. Shaqil Kassam

  Feb 17, 202627 minS0

  <p> 👉 Visit https://oncoassist.com/ to streamline patient care with cutting-edge tools, treatment protocols, and calculators! </p><p>🔬In this episode of Oncology Spotlight, Dr. Shaqil Kassam shares a powerful perspective from the front lines of community oncology in Canada.</p><p>From drug access delays in publicly funded systems to the real-world challenges of administering bispecific therapies outside academic centers, this conversation dives into the complexity of modern oncology.</p><p>We also explore:</p><p>Community vs academic oncology – what truly differs?</p><p>The global equity gap in cancer care</p><p>How AI is already transforming clinic wor...

  ListenShow Notes

Recent guests on Oncology Spotlight. Study who booked and why before you pitch.

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.